TSHA - After recent weakness gene therapy space offers a compelling opportunity: BTIG

dinn/iStock via Getty Images BTIG analysts Yun Zhong and Xu Zou witness “an attractive opportunity in gene therapy” after seeing that many players in the field are trading closer to “52-week low than to the 52-week-high.” The gene therapy candidates will see an “accelerated translation from the lab to the clinic,” thanks to improving knowledge on human biology and persistent innovation in technology, the firm noted. Following the recent FDA scrutiny on manufacturing and safety concerns, “we believe the recent weakness in the sub-sector is nothing but a maturing process,” the analysts argue as they initiate the coverage of several stocks with bullish ratings. Applied Genetic Technologies Corporation (AGTC), AVROBIO (AVRO), Magenta Therapeutics (MGTA), Passage Bio (PASG), Sarepta Therapeutics (SRPT), Selecta Biosciences (SELB), Sio Gene Therapies (SIOX), Taysha Therapeutics (TSHA), and uiQure (QURE) have all received buy ratings from BTIG. Recently, RBC Capital Markets expanded its coverage of gene-editing space.

For further details see:

After recent weakness, gene therapy space offers a compelling opportunity: BTIG